Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

Status Completed

Clinical Trial Summary

Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival related to the patient, in a prospective cohort of patients over 60 with AML diagnosis in Spain and treated outside of clinical trials; that is, under conditions of standard clinical practice. The study will last 24 months in total from the inclusion of the first patient until the end of the last patient's follow-up

Clinical Trial Description

Following the baseline enrolment visit, the following data corresponding to the patient's visits scheduled according to routine clinical practice will be collected in accordance with the following model: 1. Recruitment period: One year of recruitment period, data collection at the baseline visit, every 3 months in one year (month 3, 6, 9 and 12). 2. Follow-up period: data collection at the baseline visit, every 3 months in one year (month 3, 6, 9 and 12). The patient clinical history and the study´s questionnaires will be the source documents. The study will be carried out in the facilities of the Hematology and Hemotherapy Services of the participating centers, collecting the conditions of medical action according to the standard clinical practice. Being an observational study, no intervention out of standard clinical practice will be performed. No additional diagnostic or treatment procedures will be applied for the patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03435341
Study type	Observational
Source	Celgene
Contact
Status	Completed
Phase
Start date	February 28, 2018
Completion date	April 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319587` - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Active, not recruiting	`NCT04090736` - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy	Phase 3
Completed	`NCT01617226` - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS	Phase 2
Terminated	`NCT00957580` - Trial of Pimasertib in Hematological Malignancies	Phase 2
Terminated	`NCT00916045` - Pilot Study of Unrelated Cord Blood Transplantation	Phase 2
Completed	`NCT00640796` - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors	Phase 1
Completed	`NCT00458250` - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H	Phase 1
Active, not recruiting	`NCT05424380` - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS	Phase 1
Completed	`NCT01690624` - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse	Phase 1
Recruiting	`NCT05471700` - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients	Phase 1/Phase 2
Not yet recruiting	`NCT05016063` - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia	Early Phase 1
Not yet recruiting	`NCT04450784` - ObServatory Children Acute RElated Therapy Leukemia
Recruiting	`NCT04265963` - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT04968860` - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting	`NCT03793517` - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT	Phase 2/Phase 3
Terminated	`NCT02841540` - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes	Phase 1
Recruiting	`NCT05453903` - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies	Phase 1
Completed	`NCT03720366` - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients	Phase 1
Withdrawn	`NCT04230564` - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated	`NCT03761069` - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias	Phase 1